Citations 2
Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer
Tamura, Koji , Hata, Tatsuo , Suenaga, Masaya, Abe, Toshiya , Macgregor-Das, Anne , Borges, Michael , Wolfgang, Christopher L. , Weiss, Matthew J. , He, Jin , Petersen, Gloria M. , Gallinger, Steven , Rustgi, Anil K. , Zogopoulos, George , Potash, James B. , McCombie, W. Richard , Zandi, Peter P. , Pirooznia, Mehdi , Kramer, Melissa , Parla, Jennifer, Eshleman, James R. , Roberts, Nicholas J. , Hruban, Ralph H. , Pirooznia, Mehdi , Tamura, Koji , Yu, Jun , Shindo, Koji , Canto, Marcia Irene , Syngal, Sapna , Brand, Randall E. , Olson, Sara H. , Stoffel, Elena M. , Coté, Michele L. , Goes, Fernando , Klein, Alison P. , Goggins, Michael
Proceedings of the National Academy of Sciences | April 19, 2018 | Volume: 115 | Issue: 18 | Pages: 4767-4772
Significance Much of the inherited susceptibility to pancreatic cancer remains unexplained. Germline variants that cause protein misfolding and impaired secretion of pancreatic enzymes such as CPA1 (encoding carboxypeptidase A1) can cause pancreatic acinar cell endoplasmic reticulum (ER) stress. We investigated the hypothesis that pancreatic cancer could arise from germline variants in genes encoding pancreatic secretory enzymes that induce pancreatic acinar cell stress. We find ∼1% of 1,579 patients with pancreatic cancer vs. 1 of 2,012 controls have germline variants in the genes encoding CPA1 and CPB1 (carboxypeptidase B1) that impair secretion of its protein product and induce ER stress. These findings implicate pancreatic acinar cell stress as a mechanism of pancreatic cancer susceptibility.
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Roberts, Nicholas J. , Norris, Alexis L. , Petersen, Gloria M. , Bondy, Melissa L. , Gallinger, Steven , Kurtz, Robert C. , Olson, Sara H. , Rustgi, Anil K. , Schwartz, Ann G. , Zogopoulos, George , Ali, Syed Z. , Axilbund, Jennifer E., Chaffee, Kari G. , Childs, Erica J., Herman, Joseph M. , Kramer, Melissa , Makohon-Moore, Alvin P. , McCombie, W. Richard , McMahon, K. Wyatt, Niknafs, Noushin , Parla, Jennifer, Pirooznia, Mehdi , Potash, James B. , Rhim, Andrew D. , Smith, Alyssa , Wolfgang, Christopher L. , Wood, Laura D. , Zandi, Peter P. , Karchin, Rachel , Eshleman, James R. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Hruban, Ralph H. , Rabe, Kari G. , Brand, Randall E. , Stoffel, Elena M. , Syngal, Sapna , Chen, Yunching , Coté, Michele L. , Douville, Christopher , Goes, Fernando , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Goggins, Michael , Klein, Alison P. , Pirooznia, Mehdi
Cancer Discovery | December 9, 2015 | Volume: 6 | Issue: 2 | Pages: 166-175
Abstract Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. A familial aggregation of pancreatic cancer has been established, but the cause of this aggregation in most families is unknown. To determine the genetic basis of susceptibility in these families, we sequenced the germline genomes of 638 patients with familial pancreatic cancer and the tumor exomes of 39 familial pancreatic adenocarcinomas. Our analyses support the role of previously identified familial pancreatic cancer susceptibility genes such as BRCA2, CDKN2A, and ATM, and identify novel candidate genes harboring rare, deleterious germline variants for further characterization. We also show how somatic point mutations that occur during hematopoiesis can affect the interpretation of genome-wide studies of hereditary traits. Our observations have important implications for the etiology of pancreatic cancer and for the identification of susceptibility genes in other common cancer types. Significance: The genetic basis of disease susceptibility in the majority of patients with familial pancreatic cancer is unknown. We whole genome sequenced 638 patients with familial pancreatic cancer and demonstrate that the genetic underpinning of inherited pancreatic cancer is highly heterogeneous. This has significant implications for the management of patients with familial pancreatic cancer. Cancer Discov; 6(2); 166–75. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109